Solo 3 días para #PrimaveraSoundBarcelona 2025! 🎤 ¿Listo para verlo online y GRATIS? Nuestra guía tiene TODOS los detalles. ¡No te lo pierdas! 👉 musicanueva.es/como-ver-pri...
#PSB25 #PrimaveraSound #MúsicaEnDirecto #StreamingGratis #Festivales
A closet rod over suitcases with various blue green aloha shirts. Each occurs in a pair of large and smaller women's size or a dress. Blue with small sharks, fruit orchard, trees with birds, navy with pink bird of paradise prints
That's a wrap on the conference coordination with @alexmorgan.bsky.social for this round of @pacsym.bio #psb25
#PSB25 Of potential interest to attendees
She also talks about inclusion & exclusion criteria that would make it less likely to see someone with really high Tau and really high second biomarker (Simpson's paradox)
In the end, she thinks there is a common mechanism at play for at least some of these co-pathologies, but non-linearly
#PSB25
He continues: can you untangling these co-pathologies, i.e., whether they are attributable to some common upstream factor?
Her answer: "You're right, I didn't get into the details of this," and she goes on to explain some hints in the data but that this difficult to tease out
#PSB25
Now, some audience questions
In reply to first question, she points out some co-pathologies have large effect size, other small
@proflhunter.bsky.social is impressed by the research and also depressed by the lack of big progress on Alzheimer disease
#PSB25
She concludes with: 30-40% of variance in cognitive decline in Alzheimer disease remains unexplained
#PSB25
She describes Alzheimer disease biomarker research as a very non-linear, high-dimensional space
It involves interactions between discrete pathologies
Lifestyle also will impact the disease trajectory, and we have to understand that, as well
She discusses adaptive trial designs
#PSB25
#PSB25 Of potential interest to attendees
The biomarkers that are known to date have limited explanatory power in Alzheimer disease progression
One reason is that co-pathologies in the brain are common and in 200+ pairings, some rare
These pairings dilute the signal for hypothesized improvements in clinical course manifest in RCTs
#PSB25
I lost the live-thread I was making of this #PSB25 keynote talk by Duygu Tosun-Turgut of UCSF on biomarkers in Alzheimer disease
I will try to capture a few key ideas
#PSB25
He is now talking about how LDL/HDL are non-specific, but informative
He lists a variety of issues that are currently unresolved in the field of AI or ML-enabled biomarkers in neuropsychiatric illnesses
#PSB25
He also cites children with autism spectrum disorder as a population who could benefit from early diagnosis
He says in contrast to cardiovascular disease, there is a more brief window for biomarkers in neuropsychiatric context to be helpful to a patient
He notes lower prevalence than CVD
#PSB25
He discusses predictive biomarkers for prevention in neuropsychiatric illnesses as a goal
He is concerned that once symptoms begin, irreversible changes in the brain have already occurred
He cites mild cognitive impairment in Alzheimer disease as an example
#PSB25
He talks about how genomic predictors might permit what otherwise appears to be fate to be modifiable by lifestyle (my rough paraphrasing of what he said)
He is now talking about the brain and neuropsychiatric illnesses.
#PSB25
He says that prevention has been the primary role of cardiology and primary medicine
(*Is this a view shared by all? Reimbursement for prevention vs. rescue hints otherwise IMO)
He talks about big data studies finding people with risk for disease early on.
#PSB25
Now, a talk discussing the primacy of prevention
He starts by discussing progress in cardiology. Initially, an MI occurred, then the hospital did what they could
Neurology has been the same way, he explains
But in recent decades, Framingham identified the role of LDL
#PSB25
Next up in at #PSB25, @proflhunter.bsky.social discussing the Data Parasite Awards. Our Research Symbiont Awards researchsymbionts.org have been delayed this year, but I hope to be able to present them later in the year.
Thank you to all the organizers & participants for an amazing #psb25. This was the 30th anniversary of the symposium! It was rewarding to see so many former students & their trainees & their trainees' trainees :)
Idea shared with me at #PSB25 paraphrased in discussion of Jobs' admonition not to let the noise of other people's idea drown out your voice
"If you travel alone, you learn what you want to do. If you travel with a partner, there is a third person who isn't either of you when you decide what to do"
She is @dnalawyer.bsky.social on here
#PSB25
Thank you!
#PSB25
She recommends a variety of steps for industry/developers and regulatory bodies
#PSB25
She anticipates more litigation, increased legal risks, hindered market entry
#PSB25
WV v EPA embraced the major question doctrine, invites the courts to require more explicit guidance on ambiguities in regulations
She explains Loper Bright as the decision that actually overturned Chevron deference
Corner Post extended timeframe to challenge regulatory decisions
#PSB25
She cites her 2023 work presented here on cases bearing on algorithmic fairness
WV vs EPA
Dobbs
Loper Bright v Raimindo
SEC v Jarskey 2024
Corner Post v Board of Governors
#PSB25
That leads to the need to hybridize authorized processes
Now a definition of Chevron deference, which basically says courts should defer (within reason) to agency interpretation of a statute given regulatory expertise
#PSB25
She enumerates the 7 steps
Main takeaway is the FDA is beholden to the regulatory authority given it by the previously mentioned Act plus 21st Century Cures Act
#PSB25
Hot off the press, the FDA yesterday issued two sets of guidance yesterday
Draft guidance articulates a 7 step process
#PSB25
